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A sulfated polysaccharide, curdlan sulfate (CRDS) with 1,3-b-D-glucan as a main chain, inhibits HIV-1 infection of human
peripheral blood lymphocytes (PBLs) by binding to the V3 region of gp120. We previously showed that T cell (T)-tropic HIV-
1 isolates are over 10-fold more sensitive to neutralization by CRDS than macrophage (MT)-tropic viruses, which posseses
a relatively less charged amino acid composition in the V3 sequence. To analyze the interaction of CRDS with V3 and its
association with neutralization sensitivity of HIV-1 isolates, we examined the effect of CRDS on the binding of neutralizing
antibodies to monomeric and oligomeric gp120 mutants of T- and MT-tropic HIV-1 clones in which the V3 loop was either
deleted or substituted by V3 of another isolate. Our results showed that the presence and the amino acid composition of
the V3 loop appears to determine the extent of interaction of CRDS with the V2 and CD4-binding regions on native gp120
monomers; however, the positive charge of V3 has less effect on this interaction on oligomeric gp120. Furthermore, our
results established that only the CRDS-induced masking of V3 on oligomeric gp120 appears to be associated with the anti-
HIV-1 activity of CRDS in vitro. Our findings underline the usefulnes of CRDS for understanding the structural constraints
on gp120 that drive the transition from MT- to T-tropic isolates in vivo and enable the virus to use multiple fusion cofactors.
q 1996 Academic Press, Inc.
INTRODUCTION amino acids in the V3 loop of gp120 provides a target for
negatively charged sulfated polysaccharides (Callahan et
A major challenge in the design of therapeutic ap-
al., 1991) and that this binding leads to inhibition of HIV-
proaches for controlling HIV-1 infection is the biological
1 infection in vitro by interfering with the membrane fusion
heterogeneity of the virus itself. Primary HIV-1 isolates
process (Callahan et al., 1991; Jagodzinski et al., 1994).
differ in tropism, replicative pattern, cytopathogenicity,
Comparative studies of anti-HIV activity of polyanionic
sensitivity to soluble CD4, and serum neutralization (Levy,
compounds indicated that their effects on conformation
1993). A segment of the viral envelope gene containing
of gp120 and the gp120 – CD4 interaction as well as their
the V3 region participates in postbinding events that are
biological activity may depend upon the chemical struc-
necessary for viral entry and infection (Freed et al., 1991)
ture of these compounds. For example, among several
and has been found to be the principal determinant of
sulfated polysaccharides and sulfonic acid dyes which
tropism for macrophages (Hwang et al., 1991). Some au-
include dextran sulfate (DS), CDRS, heparan sulfate, pen-
thors report that the V3 loop alone is sufficient to confer
tosan sulfate, sulfated a- and b-cyclodextrin, aurin tricar-
macrophage tropism (Hwang et al., 1991), while others boxylic acid, Evans blue and Chicago sky blue, only aurin
maintain that additional segments are required for maxi-
tricarboxylic acid and Evans blue inhibited the CD4 –
mum efficiency (Kim et al., 1995; Koito et al., 1995). It has
gp120 binding, whereas the others had only a minimal
been suggested that a relatively high number of basic
effect on this interaction (Callahan et al., 1991; Jagodzin-
ski et al., 1994; Clanton et al., 1992). Anti-HIV-1 and anti-
coagulant activities of DS were found to be largely de-1 Permanent address: Department of Physiological Chemistry, K.
Marcinkowski University School of Medical Sciences, Poznan, Poland. pendent upon molecular mass (Baba et al., 1988). Also,2 To whom correspondence and reprint requests should be ad-
the lower suppressive effect of CRDS on T cell functiondressed. Fax: (215) 762-3529. E-mail: Kozbor@Allegheny. edu.
as compared to DS might be related to the b type of3 Present address: Center for Neurovirology, Allegheny University of
the Health Sciences, Broad and Vine Steets, Philadelphia, PA 19102. glucopyranosyl linkage of CRDS versus the a type of
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linkage of DS (Jagodzinski et al., 1994). These observa- lap the binding site for the CD4 receptor (Posner et al.,
1991; Thali et al., 1991); G3-42 and G45-60, mouse mAbstions, together with the nonantigenicity of CRDS, and its
10-fold lower anticoagulant activity relative to heparin in (MmAbs) directed against epitopes located in the C4
region of gp120 [G3-42 recognizes a core epitope in theguinea pigs and rats (Kaneko et al., 1991), have led to
the initiation of clinical trials of CRDS in HIV-infected C4 region of gp120, but in comparison with F105 HmAb,
it is poorly neutralizing and sensitive to amino acidindividuals (Gordon et al., 1995).
Because of the anticipated use of CRDS as a broadly changes in the V3 region (Moore et al., 1993)]; 0.5b and
G3-523, MmAbs directed against a linear epitope locatedneutralizing agent against a wide variety of HIV-1 iso-
lates, we extended our previous analysis to examine the within the V3 loop (Matsushita et al., 1988); 447-52-D, a
HmAb that recognizes the top of the V3 loop in a relativelyinteraction of CRDS with the V2, V3, and CD4-binding
domains of monomeric and oligomeric gp120 mutants broad range of HIV-1 isolates (Gorny et al., 1993); G3-4,
a MmAb that recognizes a discontinuous conformation-with a deletion in the V3 loop of the HTLV-IIIB isolate or
with a substitution by V3 of the BaL isolate. Our results dependent epitope in the V2 region (Ho et al., 1991); and
T11, a MmAb specific for a linear epitope in the C1 regionshow that interaction of CRDS with the V2 and C4 regions
on monomeric gp120 is largely dependent upon the pres- of gp120 (Earl et al., 1994). W6/32 is a MmAb specific
for the nonpolymorphic determinant of human MHC classence and the amino acid composition of the V3 region.
In contrast, the positive charge of V3 has less effect on I molecules, HSP 72/73 is a MmAb specific for heat shock
proteins (HSP) 72/73, and Leu3a (Becton-Dickinson,the interaction of CRDS with C4 or V2 on oligomeric
gp120. Furthermore, the degree of reactivity of CRDS with Mountain View, CA) is a MmAb which reacts with an
epitope on the CD4 protein located within the NH2-termi-the V3 loop on the oligomeric envelope glycoprotein of
T- and MT-tropic viruses is associated with neutralization nal domain 1. HmAbs F105 and 447-52-D were generous
gifts from Dr. M. Posner (New England Deaconess Hospi-sensitivity of HIV-1 during infection of T lymphocytes.
tal, Boston, MA) and Dr. S. Zolla-Pazner (Veterans Affairs
Medical Center, New York, NY), respectively; MmAb T11MATERIAL AND METHODS
was provided by Dr. R. Doms (University of Pennsylvania,
Cell lines Philadelphia, PA); MmAb 0.5b was obtained from the NIH
AIDS Research and Reference Reagent Program (Rock-Peripheral blood mononuclear cells (PBMC) were ob-
ville, MD); MmAb HSP 72/73 from Oncogen Sciencetained from HIV-1-seronegative donors (North American
(Cambridge, MA), and MmAb W6/32 was a gift from Dr.Biologicals, Inc., Miami, FL) after centrifugation over Fi-
G. Trinchieri (The Wistar Institute, Philadelphia, PA).coll-Hypaque (density 1.077 g/cm3). Before HIV-1 infec-
tion, cells were stimulated with 1% PHA (Murex Diagnos-
Envelope glycoproteins and HIV-1 proviral clonestic Ltd., Darford, England) and maintained in RPMI 1640
culture medium (Gibco BRL, Gaithersburg, MD) con-
The HIV-1 (HxB2 substrain of the HTLV-IIIB isolate) enve-taining 50 U/ml of rIL-2 (NIH AIDS Research and Refer-
lope glycoproteins of the wild-type (WT) and the DV3 mu-ence Reagent Program, Rockville, MD) as described
tant were a generous gift of Dr. J. Sodroski (Dana-Farber(Hwang et al., 1992). CD4/ T lymphocytes were obtained
Cancer Institute). The mutant contains a deletion spanningfrom PBMC of HIV-1-seronegative donors by cell sorting
the V3 loop (amino acids 297–329), with the sequence Gly-of Leu3a-positive cells followed by stimulation with 1%
Ala-Gly inserted in place of the loop (Wyatt et al., 1992). BothPHA and irradiated (4000 rads) monocytes. The cells
envelope glycoproteins were expressed by transfection ofwere over 95% positive for CD4 expression and were
plasmid pSVIII-env containing either the WT or the mutatedmaintained in RPMI 1640 medium supplemented with
envelope gene into COS-1 cells.rIL-2. Human rhabdomyosarcoma cells (RD-4 cells) and
The HIV-1 recombinant clones pIIIB, pBaL, and pIIIB/simian COS-1 cells were obtained from Dr. A. Srinivasan
V3-BaL were a generous gift from Dr. B. Cullen (Howard(Thomas Jefferson University, Philadelphia, PA) and Dr. J.
Hughes Medical Institute, Duke University Medical Cen-Sodroski (Dana-Farber Cancer Institute, Harvard Medical
ter, Durham, NC). The T-tropic HIV-1 clone, pIIIB, containsSchool, Boston, MA), respectively. Both cell lines were
a modified form of the replication-competent HxB3 provi-maintained as monolayer cultures in DMEM (Gibco BRL,
rus derived from the HTLV-IIIB isolate (Hwang et al.,Gaithersburg, MD). All media were supplemented with
1991). The HxB3 provirus present in the pIIIB plasmid is10% FCS and antibiotics.
similar to the published clone except that the single base
pair frame-shift mutation present in the vpr gene of HxB3Monoclonal antibodies
has been repaired (Hwang et al., 1991). At 72 hr after
transfection, the COS-1 cultures were fed with fresh me-Anti-gp120 mAbs comprised the following: F105, a hu-
man mAb (HmAb) directed against an epitope composed dium containing PHA-activated PBMC at a density of 106
cells/ml. Cells were cultivated with the transfected COS-of four discontinuous regions of gp120 that partially over-
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1 cells for 3 days, aspirated, washed, and maintained in by p24 antigen production determined by immunocapture
assay (Du Pont Company, Wilmington, DE). Because theexpanded culture for 4 more days. On Day 7 after infec-
tion, supernatants were removed, filtered through a 0.45- growth rate of IL-2-dependent T lymphocytes is lower at
concentrations of CRDS 50 mg/ml, cells in all culturesmm filter, and virus stocks were stored at 0707.
were resuspended to a density of 106 cells/ml and super-
Immunoprecipitation natants were harvested after 24 hr to monitor p24 antigen
levels.
COS-1 cells were transfected with 10 mg of pSVIIIenv
DNA expressing the WT or the DV3 mutant by the DEAE- Indirect flow cytometry and blocking assays
dextran technique (Cullen, 1987), whereas RD-4 cells
were transfected with 10 mg of the HIV-1 proviral DNA CD4/ T lymphocytes infected for 7 days with 1000
TCID50 per milliliter of pIIIB, pIIIB/V3-BaL, or pBaL wereby the calcium phosphate method (Cullen, 1987). Immu-
noprecipitations were carried out 50 – 60 hr after transfec- incubated for 30 min with anti-gp120 mAbs (1 mg/ml) in
PBS buffer containing 2% FCS and 0.1% sodium azidetion using Nonidet P-40 (NP-40) buffer (0.5% NP-40, 0.5
M NaCl, 10 mM Tris – HCl (pH 7.5)) to lyse transfected (PBS/FCS), washed three times in PBS/FCS, stained with
a 1:40 dilution of FITC-conjugated F(ab*)2 fragment ofcells after overnight labeling with 60 mCi/ml of [
35S]-
cysteine and [35S]methionine (DuPont NEN Company, goat anti-mouse or anti-human Ig (Organon Teknica Co.,
West Chester, PA), and fixed by overnight incubation withBoston, MA) in cysteine- and methionine-free DMEM me-
dium. Radiolabeled cell lysates were precipitated with 1% paraformaldehyde. Cells were washed in PBS/FCS
and analyzed on a Coulter Cytofluorograf System, PRO-anti-gp120 mAbs in the presence or absence of 50 mg/
ml of CRDS (molecular mass, 79 { 0.6 kDa, sulfur con- FILE II. For analysis of CRDS-mediated inhibition of bind-
ing of anti-gp120 mAbs to oligomeric gp120, pIIIB-, pIIIB/tent, 15.2 { 0.3%; Ajinomoto Co., Inc., Tokyo, Japan). The
cell lysate was divided into aliquots (0.5 ml) and incu- V3-BaL-, and pBaL-infected cells were incubated with
F105, G45-60, 447-52-D, and G3-4 mAbs in the presencebated with anti-gp120 mAbs followed by polyclonal rabbit
anti-mouse or anti-human antibodies (Organon Teknika or absence of CRDS, followed by FITC-conjugated sec-
ond antibody and analysis by flow cytometry.Corp., West Chester, PA) and immunocomplexes were
precipitated with protein A– Sepharose CL4B (Pharmacia
Molecular modelingBiotech, Piscataway, NJ). Samples electrophoresed on a
8% SDS – polyacrylamide gel were analyzed with a stor-
Modeled topographical CRDS/gp120 possible associ-age phosphor imager (PhosphoImager 400S; Molecular
ation was performed on a PC computer equipped withDynamics). The relative amounts of the envelope glyco-
Pentium processor and Number 9 video board using
protein were determined from the volume of pixel counts
Chem-X for Windows 95 software (Chemical Design Inc.,
in the envelope bands (Johnston et al., 1990). The labeled
Mahwah, NJ). Energy minimization and molecular dynam-
cell lysates from transfected COS-1 and RD-4 cells were
ics calculation were performed at 3017K.
coprecipitated with HSP 72/73 and W6/32 mAbs, respec-
The CRDS molecule was constructed starting with glu-
tively, to ensure loading of equivalent amounts of protein.
cose, sulfated at the sixth position of carbon. The 6-sulfo-
glucose was energy optimized in vacuum and dimerizedAnti-HIV-1 activity of CRDS
by an b-1,3 bond. Then another sulfate group was added
at the second position of carbon of the second glucoseVirus stocks derived from the indicated HIV-1 recombi-
nant clones were titrated on PHA-induced PBL by the monomer and the structure was optimized by energy
minimization in a vaccum. The CRDS unit used for furtherend-point-dilution method (Dulbecco, 1988). All stocks
were titrated in replicate cultures of PBL derived from a modeling was composed of nine such molecules. This
structure was further optimized by energy minimizationsingle donor in flat-bottom wells of 96-well tissue culture
plates in RPMI 1640 medium with rIL-2. The median num- in conditions simulating the presence of the water sol-
vent. The distance between sulfated groups in each unitber of tissue culture infectious doses (TCID50) of HIV-1
per milliliter was taken as the inverse of the highest of CRDS was as follows: 6.4 A˚ is the distance between
sulfated groups at the sixth position of carbons of thedilution that resulted in infection of 50% of the replicate
cultures (Hwang et al., 1992). To measure anti-HIV-1 ac- first and the second monomers; 11.3 A˚ is the distance
between sulfated groups at the sixth position of carbonstivity of CRDS, virus stocks were diluted to 1000 TCID50
per milliliter of medium and incubated without or with of the second and the third monomers; 15.8 A˚ is the
distance between sulfated groups at the sixth position0.1– 100 mg/ml CRDS at 377 for 30 min before addition
to 106 PHA-stimulated PBL (Jagodzinski et al., 1994). Cells of carbons of the first and the third monomers; 20.4 A˚ is
the distance between sulfated groups at the sixth posi-were washed and cultured with or without CRDS in me-
dium containing 50 U/ml of rIL-2. Cells were fed twice a tion of carbons of the first and the fourth monomers.
The secondary structure of the CRDS polymer includesweek and virus was sought in the cell-free supernatant
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sulfate groups that form a well-pronounced edge winding to several regions of envelope glycoproteins, its effect
on the neutralizing epitopes of gp120 is largely V3 loop-along the glucose backbone.
The nucleotide sequence of the HxB2 gp120 was ob- dependent.
tained from GenBank (Accession No. M38432), and the
Inhibition of T- and MT-tropic HIV-1 recombinantproposed positions of the V2, V3, and C4 structures were
clones by CRDSbased on models by Gabriel and Mitchell (1993) and
Choe and Sodroski (1995). The molecular modeling of
Because the V3 loop of MT-tropic isolates carries
the secondary structure of the V2, V3, and CD4-binding
lower concentrations of positive charges as compared
domains of gp120 was carried out in several identical
to T-tropic variants (Hwang et al., 1991), we studied
steps: (i) a randomly coiled structure generated by Chem-
whether the V3 loop of BaL confers lower susceptibility
X was submitted to geometric energy minimization, with
to CRDS neutralization when transferred onto the IIIB
constraints limiting the distance between sulfur atoms
background (Fig. 2A). Analysis of p24 antigen levels in
of amino- and carboxyterminal C residues to 5 A˚ (usually
culture supernatants of PHA-induced PBL infected with
between 50 and 100 minimization cycles were sufficient
pIIIB, pBaL, and pIIIB/V3-BaL viruses after 3, 6, 9, and
to bring C residues to the required distance); (ii) a disul-
12 days of infection revealed a 10-fold reduction in
fide bond was formed between these C residues; (iii) sensitivity to CRDS-mediated inhibition of pBaL as com-
further nonconstrained minimization was performed until pared to that of pIIIB: the IC50 (50% inhibitory concentra-reaching the convergence conditions, usually between tion) for CRDS ranged from 20.0 to 29.0 mg/ml for pBaL
300 and 600 cycles; and (iv) molecular dynamics was
and 2.1 to 3.5 mg/ml for pIIIB (Fig. 3A). Complete inhibition
performed for 1 psec, followed by energy minimization
of infection with pIIIB and pBaL was achieved with CRDS
(100 cycles), molecular dynamics for 10 psec, and final
at concentrations of 10 and 100 mg/ml, respectively (Figs.
energy minimization. Calculations were performed using
3B and 3D). Supernatants collected from CRDS-treated
all atom force field algorithm (Weiner et al., 1986) imple-
cultures of pIIIB-infected cells (10 and 100 mg/ml) and
mented by Chem-X.
pBaL-infected cells (100 mg/ml) at 12 days after infection
failed to infect cultures of PHA-induced PBL. The pIIIB/
RESULTS
V3-BaL recombinant virus which displayed MT tropism
(not shown) was found to be 6-fold more resistant toEffect of V3 loop deletion on interaction of CRDS
inhibition with CRDS than the pIIIB isolate (Fig. 3C). Thewith gp120
IC50 values for CRDS with pIIIB/V3-BaL ranged from 14.0To gain insight into the CRDS-induced structural to 18.0 mg/ml, and complete inhibition of infection was
changes in the envelope glycoprotein, we first compared
observed with 60 mg/ml of CRDS. The similar pattern of
the effect of a deletion encompassing the V3 region of
susceptibility of pBaL and pIIIB/V3-BaL to inhibition by
the HTLV-IIIB isolate on CRDS-mediated inhibition of
CRDS suggests that the V3 loop sequence of the BaL
binding of gp120-specific mAbs to monomeric gp120
isolate, on a IIIB background, had a profound effect on
(monomeric gp120 was derived from COS-1 cell transfec-
the resistance of the chimeric virus to CRDS-mediated
tants expressing either the WT or DV3 mutant glycopro-
inhibition.
tein). Precipitation of the WT gp120 revealed that the
inhibition of binding of anti-V3 loop-specific mAbs G3- Interaction of CRDS with the V2, V3, and C4 domains
523 and 0.5b by CRDS was lower than that of the confor- of monomeric and oligomeric gp120 molecules of
mation-dependent mAbs G3-42 and F105 directed to the pIIIB, pIIIB/V3-BaL, and pBaL
epitopes within the C4 region of gp120 (Table 1 and Fig.
1). The effect of CRDS on other domains of gp120 that The CRDS-mediated inhibition of antibody binding to
monomeric gp120 was analyzed by precipitation of RD-included the V2 loop and the C1 region was small. In the
DV3 mutant, a loss of the V3 loop-dependent masking 4 cells transfected with HIV-1 DNA of pIIIB, pIIIB/V3-BaL,
and pBaL. The profile of CRDS-mediated inhibition ofof the discontinuous epitope recognized by mAb F105
was indicated by the2-fold reduced inhibition of CRDS- antibody binding to gp120 of pIIIB (Table 2, Fig. 4A) was
similar to that of the HxB2 gp120 used for previous stud-mediated binding of this antibody (Table 1, Fig. 1). The
observed lack of reactivity with G3-42 might rest in the ies, except that the binding of T11 antibody to the C1
region was slightly increased in the presence of CRDS.sensitivity of this antibody to conformational changes in
the C4 region induced by deletion of the V3 region The CRDS-mediated inhibition of binding mAb 447-52-D
to the V3 loop GPGR core epitope was comparable in(Moore et al., 1993). In contrast, deletion of the V3 loop
sequences resulted in an increased exposure of epi- pIIIB/V3-BaL and pBaL (Figs. 4B and 4C) and 2-fold
lower than in pIIIB. The inhibition of mAb G45-60 to thetopes in V2 and C1 for interaction with CRDS as shown
by3-fold higher inhibition of binding of mAbs G3-4 and linear epitope in C4 (Fig. 4D) was lower in pIIIB/V3-BaL
than in pIIIB, and was further decreased in pBaL (TableT11. These results suggest that although CRDS can bind
AID VY 8266 / 6a25$$$481 11-12-96 22:26:32 viras AP: Virology
221ANTI-HIV-1 ACTIVITY OF SULFATED POLYSACCHARIDES
FIG. 1. Precipitation of the WT and DV3 mutant envelope glycoproteins by gp120-specific mAbs. COS-1 cell transfectants expressing either WT
or DV3 gp120 were lysed in NP-40 buffer and precipitated with the indicated mAbs in the presence or absence of 50 mg/ml of CRDS. The radiolabeled
cell lysates were coprecipitated with mAb HSP 72/73 to ensure loading equivalent amounts of protein. Results are representative of three separate
experiments.
2), despite a good homology of the linear sequences and pBaL was comparable and over threefold lower than
in pIIIB-infected cells (Table 2). However, as opposed tobetween the C4 region in both HxB2 and BaL (Fig. 2B).
Similar results were obtained with F105 mAb. The epi- the results with monomeric gp120, the levels of the
CRDS-mediated inhibition of mAb F105 and G45-60 bind-tope in the V2 loop of pIIIB/V3-BaL was slightly more
accessible to CRDS binding than in the V2 region of pIIIB, ing to their respective epitopes on gp120 oligomers was
similar in pIIIB and pIIIB/V3-BaL and 20% lower inwhereas lack of binding of mAb G3-4 to the V2 loop of
pBaL precluded analysis of CRDS-induced conforma- pBaL. In addition, we did not observe CRDS-mediated
inhibition of the binding of mAb G3-4 to the V2 region oftional changes in this region.
The CRDS-mediated inhibition of antibody binding to the pIIIB and pIIIB/V3-BaL oligomeric gp120. Thus, the
accessibility of the epitopes recognized by mAbs againstthe neutralizing domains on oligomeric gp120 molecules
was analyzed on CD4/ T lymphocytes infected with 1000 C4 on oligomeric gp120 of pIIIB and pIIIB/V3-BaL was
less affected by the differences between interaction ofTCID50 per milliliter of pIIIB, pIIIB/V3-BaL, or pBaL. Using
immunofluorescence staining and flow cytometric analy- CRDS with the V3 loop as compared to the native gp120
monomers. These results, together with those of thesis, we observed that the CRDS-induced inhibition of
mAb 447-52-D binding to the V3 region in pIIIB/V3-BaL CRDS-induced inhibition of infection by T- and MT-tropic
TABLE 1
Effect of CRDS on Binding of Anti-gp120 mAbs to WT and DV3 Mutant Envelope Glycoproteins
Percentage of CRDS-mediated inhibition
of antibody binding to gp120a
mAbs Specificity Epitope WT gp120 DV3 mutant gp120
T11 C1 102– 125 EQMHEDIISLWDQSLKPCVKLTPL 8.8 { 2.0 27.0 { 1.4
G3-4 V2 loop 176– 184 FYKLDIIPI 11.3 { 0.5 34.0 { 5.4
191– 193 YSL
G3-523 V3 loop 308– 322 RIQRGPGRAFVTIGK 43.0 { 2.3 NDb
0.5b V3 loop 312– 322 GPGRAFVTIG 51.0 { 3.1 ND
F105 CD4-binding site 256/257 ST 75.0 { 4.5 42.0 { 4.0
of gp120c 368/369/370 DPE
421 K
470– 484 PGGGDMRDNWRSELY
G3-42 C4 429– 438 KVGKAMYAPP 64.0 { 2.8 ND
a Immunoprecipitates of the WT and DV3 mutant glycoproteins in the presence or absence of CRDS (50 mg/ml) were analyzed on SDS –
polyacrylamide gels and the relative intensity of bands representing gp120 was determined by integration of pixel volume corresponding to the
amount of radioactivity in the glycoproteins (Johnston et al., 1990). Percentage inhibition of antibody binding in the presence of CRDS was calculated
as 100 1 (1 0 Xa/Xc), where X is the pixel count in gp120 bands immunoprecipitated from COS-1 transfectants in the presence (Xa) or absence
(Xc) of CRDS after subtracting background values. Results are presented as mean { SD from three experiments.
b ND, not detected.
c Three of the four regions of gp120 are proximal to those previously shown to be important for CD4 binding (Thali et al., 1991).
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FIG. 2. Restriction enzyme analysis of chimeric HIV-1 clones and predicted amino acid sequences of the V2 and V3 loops and the C4 region of gp120
of HxB2 and BaL. (A) Construction of HIV-1 clones in which BaL sequences (in black) corresponding to the envelope glycoprotein or the V3 loop were
substituted onto the pIIIB clone has been described (Hwang et al., 1991). The nucleotide sequence of the HxB2- and BaL-specific segments are available
from GenBank (Accession Nos. M38432 and M68893, respectively). Abbreviations for the restriction enzyme sites are as follows: A, AccI; B, BamHI; D,
DraI; K, KpnI; S, SalI; and X, XhoI. (B) The V2, V3, and C4 domain amino acid sequences of HxB2 and BaL envelope glycoproteins used for mAb binding
studies were aligned, starting at the amino-terminal cysteine. Amino acid positions are designated with respect to the sequence of HxB2-gp120. Identity
of the amino acid sequence in HxB2 and BaL is indicated by dots and deletion by dashes.
isolates, indicate that the V3 loop of oligomeric gp120 The V2 positively charged residues (R166, K168, K171,
and K178) are more scattered and, additionally, are inter-appears to be the major determinant of the neutralization
spersed with negatively charged E172 and D180 aminosensitivity of HIV-1 in vitro.
acids. This makes the epitope for the G3-4 antibody V2
region not readily accessible for CRDS. Within the C4Proposed interaction of CRDS with the V2, V3, and C4
region, three (R419, K421, and R444) of five positivelyregions of gp120 by molecular modeling
charged residues are located very close to the disulfate
The automated fitting procedure of Chem-X, used to bridge, which makes them less likely available for inter-
investigate the possibility of complex formation between action with CRDS. The remaining K429 and K432 resi-
the neutralizing domains of gp120 and CRDS, revealed dues that are located near or within the epitope of G45-
that the V3 domain represents the most probable site for 60 mAb may not provide sufficient positive charge to
the interaction with CRDS (Fig. 5). The V3 loop with six be solely responsible for the 60% of CRDS-mediated
positively charged amino acid residues located near and inhibition of binding of the G45-60 mAb. Rather, the ob-
at the top of the loop (R304, K305, R306, R308, R311, served inhibition of antibody binding to this region might
and R315) create a positively charged patch which may be due to some unfolding of the gp120 molecule after
interact and form a complex with sulfate groups at the interaction of CRDS with V3 which results in masking of
the C4 domain. This effect might be further augmentedsixth position of carbon in each glucose unit of CRDS.
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FIG. 3. Concentration-dependent neutralization of pIIIB, pIIIB/V3-BaL, and pBaL by CRDS. (A) Activated PBL were exposed to HIV-1 proviral clones
for 2 hr at 377 in the presence or absence of CRDS, washed, and cultured with CRDS. At 8 days after infection, cells were resuspended to a density
of 106 cells/ml and culture supernatants were harvested after 24 hr to analyze p24 antigen production. Results are representative of three separate
experiments and are means of triplicate values with standard deviation (SD) 15%. (B– D) Activated PBL were exposed to pIIIB (B), pIIIB/V3-BaL
(C), and pBaL (D) for 2 hr at 377 in the absence (D) or presence of CRDS: 0.1 mg/ml(X); 0.3 mg/ml (l); 1 mg/ml (l); 3 mg/ml (m); 10 mg/ml (Ò); 30
mg/ml (.), and 100 mg/ml (j). Cells were washed and cultured with or without CRDS for 2, 5, 8, and 11 days. Twenty-four hours before the assay,
cells were resuspended to a density of 106 cells/ml and supernatants were harvested to monitor p24 antigen levels. Results represent means of
triplicate values with SD  10%.
by the presence of K429 and K432 residues in this region. V3 loop on the oligomeric envelope glycoprotein was
associated with the neutralization sensitivity of the virus.For example, substitution of 429 K/E in gp120 of pBaL
resulted in smaller inhibitory effect of CRDS on the bind- This observation is consistent with the results of recent
studies which demonstrated structural modulations uponing of G45-60.
gp120 oligomerization determined by differences in the
efficiency of mAb binding to dominant neutralizing epi-DISCUSSION
topes on oligomeric versus monomeric gp120 molecules
In this study, we have analyzed the binding of CRDS (Sattentau and Moore, 1995; Stamatatos and Cheng-
to the V3 and V2 and CD4-binding regions of monomeric Mayer, 1995). Consequently, the sensitivity of viruses
and oligomeric envelope glycoproteins of the WT and V3 containing different envelope glycoproteins to neutraliza-
loop-deleted or chimeric mutants of the HTVL-IIIB and tion by mAbs, soluble CD4, or sulfated polysaccharides
BaL isolates. Our results showed that CRDS effect on could be predicted by assays dependent on the binding
monomeric versus oligomeric envelope glycoproteins of the inhibitory molecule to the oligomeric envelope gly-
coprotein complex but less well by assays measuringdiffers, and the extent of interaction of CRDS with the
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TABLE 2
Effect of CRDS on Anti-gp120 Antibody Binding to Monomeric and Oligomeric gp120 Molecules
Percent of CRDS-mediated inhibition of antibody binding to:
Monomeric gp120a Oligomeric gp120b
mAbs HIV-1 clones: pIIIB pIIIB/V3-BaL pBaL pIIIB pIIIB/V3-BaL pBaL
T11 08.0 { 3.2 03.1 { 0.4 09.5 { 4.5 NTc NT NT
G3-4 15.8 { 4.4 23.3 { 2.0 ND 01.5 { 0.2 00.6 { 0.1 ND
447-52-D 47.2 { 3.1 28.9 { 1.3 22.7 { 2.2 91.0 { 3.0 30.0 { 4.5 25.8 { 7.0
G45-60 38.4 { 0.8 30.2 { 2.4 10.6 { 1.3 63.0 { 6.0 60.5 { 0.8 52.2 { 1.6
F105 52.3 { 4.3 32.4 { 1.1 12.0 { 1.4 59.5 { 5.5 52.1 { 4.5 45.0 { 2.8
a Mean values { SD from three independent immunoprecipitation experiments of monomeric gp120 molecules.
b Percentage of CRDS-mediated inhibition of binding of anti-gp120 antibodies to oligomeric gp120 on the surface of HIV-1-infected cells was calculated
as 100 0 (MFx 0 MFo)/(MFc 0 MFo) 1 100, where MF is the mean fluorescence intensity of infected cells stained with anti-gp120 antibody in the
presence (MFx) or absence (MFc) of CRDS (50 mg/ml). Controls represent fluorescence with labeled antibodies alone (MFo). Results are presented as
means { SD from three experiments.
c NT, not tested.
binding to the monomeric gp120 glycoprotein (Sattentau effect on virions, the CD4 receptor, and inhibited weakly
HIV-1 attachment to cells (Jagodzinski et al., 1994). Ourand Moore, 1995; Sullivan et al., 1995).
In view of the complexity of the HIV-1 replicative cycle, recent studies indicate that CRDS does not induce global
conformational changes of gp120 but exerts its anti-HIV-several stages of replication might represent potential
targets for anti-HIV-1 therapy. We have shown that CRDS 1 activity through a specific interaction with the V3 loop
of gp120. These results may be important in understand-exert their anti-HIV-1 activity by interfering with the mem-
brane fusion process during HIV-1 infection but had no ing the interaction of gp120 of T- and MT-tropic isolates
FIG. 4. Immunoprecipitation of envelope glycoproteins of HIV-1 clones. Immunoprecipitation of pIIIB (A), pIIIB/V3-BaL (B), and pBaL (C) from RD-
4 transfectants was carried out in NP-40 buffer with and without CRDS (50 mg/ml) using gp120-specific mAbs. Immunoprecipitation of the C4 domain
of HIV-1 clones from RD-4-transfected cells was performed with mAb G45-60 (D). The radiolabeled cell lysates were coprecipitated with anti-MHC
class I mAb W6/32 to ensure loading equivalent amounts of protein. Results are representative of three separate experiments.
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FIG. 5. Proposed structural features of the modeled association between CRDS and the V2, V3, and CD4-binding regions of gp120. The numbering
system is as defined in Fig. 2 with V2 in blue, V3 in purple, and C4 in green. CRDS is orange with 1,3-b-D-glucan as a main chain in light green
and sulfate groups in yellow. Regions of gp120 between V2, V3, and C4 are shown in gray.
with recently described chemokine receptors during the quence variation in vivo. In Phase I clinical trials, CRDS
was found in 4-hr intravenous infusions to be well toler-membrane fusion process. It has been shown that a co-
factor for T-tropic HIV-1 isolates is a seven-transmem- ated up to 200 mg/70 kg. The plasma level of CRDS
varied between 20 and 40 mg/ml with CRDS doses rang-brane domain protein, named fusin (Feng et al., 1996),
whereas the fusion cofactors for primary MT-tropic ing from 150 to 200 mg/70 kg (Gordon et al., 1995). These
concentrations of CRDS are quite effective in blockingstrains of HIV-1 are receptors for the b-chemokines
RANTES, MIP-1a, and MIP-1b (Deng et al., 1996; Dragic infection of T-tropic isolates and significantly inhibit in-
fection with MT-tropic strains in vitro. It has been sug-et al., 1996). Because the structure of the V3 loop can
influence the ability of HIV-1 viruses to respond to the gested that the T-tropic viruses characteristic of disease
progression may evolve from MT-tropic viruses prevalentpresence of these b-chemokine receptors in the target
cells (Choe et al., 1996), CRDS through its binding to early in virus infection through changes in the envelope
protein that enable the virus to use multiple entry cofac-V3 may be useful in understanding the cellular events
underlying source of permissiveness for MT- and T-tropic tors (Doranz et al., 1996). The ‘‘phenotypic switch’’ of the
HIV-1 virus from MT to T-cell tropism during progressionviruses.
The most critical questions concerning CRDS and to AIDS raises the possibility that HIV-1 uses the b-chem-
okine receptors early in the course of infection and thenother polyanionic compounds is their clinical applicability
against primary HIV-1 isolates regardless of their se- later switches to fusin-like molecules, perhaps by
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primary HIV-1 isolate that uses fusin and the b-chemokine receptorsavoiding the suppressive activity of the chemokines and
CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85, 1149–1158.broadening the number of cell types it can attack (Balter,
Dragic T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima,1996). Thus, if the appearance of T-tropic isolates contri- K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., and Paxton,
butes to disease progression in vivo, then CRDS might W. A. (1996). HIV entry into CD4/ cells is mediated by the chemokine
prove clinically useful despite its relatively lower effec- receptor CC-CKR-5. Nature 381, 667– 673.
Dulbecco, R. (1988). The nature of viruses. In ‘‘Virology’’ (R. Dulbeccotiveness against the MT-tropic HIV-1 isolates.
and H. S. Ginsberg, Eds.), 2nd ed., pp. 1– 26. Lippincott, Philadelphia/Our findings underline the usefulness of CRDS and
London/Mexico City/New York/St. Louis/San Paulo/Sydney.other sulfated polysaccharides capable of specific in-
Earl, P. L., Broder, C. C., Long, D., Lee, S. A. Peterson, J., Chakrabarti,
teraction with the V3 loop in helping to establish the S., Doms, R. W., and Moss, B. (1994). Native oligomeric human immu-
structural changes of gp120 associated with the switch nodeficiency virus type 1 envelope glycoprotein elicits diverse mono-
clonal antibody reactivities. J. Virol. 68, 3015 –3026.from MT- to T-cell tropism in vivo. Such analyses are
Feng, Y., Broder, C. C., Kennedy, P. E., and Berger, E. A. (1996). HIV-1important in the search for novel anti-HIV-1 agents that
entry cofactor: functional cDNA cloning of a seven-transmembraneact independently of reverse transcription and will lead
domain, G-protein coupled receptor. Science 272, 872– 877.
to a better understanding of the role of different regions Freed, E. O., Myers, D. J., and Risser, R. (1991). Identification of the
of gp120 in cellular tropism and other biological prop- principal neutralizing determinant of human immunodeficiency virus
erties of HIV-1. type 1 as a fusion domain. J. Virol. 65, 190 –194.
Gabriel, J. L., and Mitchell, W. M. (1993). Proposed atomic structure
of a truncated human immunodeficiency virus glycoprotein gp120
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